Ronald E Blaylock bought $499K of Pfizer (PFE)
Executed Feb 13 2025, disclosed Feb 14 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Feb 14 2025), the stock returned +1.2% (delay-adjusted); from the execution session (Feb 13 2025), +0.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ronald E Blaylock (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Pfizer Inc. (PFE). Across 1 priced purchase filing, the average 21-session return was +0.9% from execution and +1.2% from disclosure (delay-adjusted; derived). The largest single filing was $499K of PFE (19,457 sh × $25.65, as filed), executed Feb 13 2025.
Healthcare · Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→